Advances in Hemophilia
Hemophilia in the 21st century: tremendous progress, tremendous opportunity

https://doi.org/10.1053/j.seminhematol.2015.10.007Get rights and content

Section snippets

Financial disclosure/conflict of interest

Dr Fogarty has received consulting fees from Bayer Healthcare, Baxter/Baxalta, Biogen, Chugai, CSL Behring, NovoNordisk, and Pfizer, Inc; has received research support from Bayer Healthcare, Baxter/Baxalta, Biogen, CSL Behring, Pfizer, Inc, and Spark Therapeutics; and is an employee of Pfizer, Inc.

References (23)

  • P.M. Aggeler et al.

    Plasma thromboplastin component (PTC) deficiency; a new disease resembling hemophilia

    Proc Soc Exp Biol Med.

    (1952)
  • Cited by (0)

    View full text